Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Br J Cancer ; 96(11): 1667-74, 2007 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-17473824

RESUMEN

Formaldehyde has been previously shown to play a dominant role in promoting synergy between doxorubicin (Dox) and formaldehyde-releasing butyric acid (BA) prodrugs in killing cancer cells. In this work, we report that these prodrugs also protect neonatal rat cardiomyocytes and adult mice against toxicity elicited by Dox. In cardiomyocytes treated with Dox, the formaldehyde releasing prodrugs butyroyloxymethyl diethylphosphate (AN-7) and butyroyloxymethyl butyrate (AN-1), but not the corresponding acetaldehyde-releasing butyroyloxydiethyl phosphate (AN-88) or butyroyloxyethyl butyrate (AN-11), reduced lactate dehydrogenase leakage, prevented loss of mitochondrial membrane potential (DeltaPsim) and attenuated upregulation of the proapoptotic gene Bax. In Dox-treated mice, AN-7 but not AN-88 attenuated weight-loss and mortality, and increase in serum lactate dehydrogenase. These findings show that BA prodrugs that release formaldehyde and augment Dox anticancer activity also protect against Dox cardiotoxicity. Based on these observations, clinical applications of these prodrugs for patients treated with Dox warrant further investigation.


Asunto(s)
Antineoplásicos/toxicidad , Ácido Butírico/farmacología , Citoprotección/efectos de los fármacos , Doxorrubicina/toxicidad , Formaldehído/farmacología , Miocitos Cardíacos/efectos de los fármacos , Organofosfatos/farmacología , Profármacos/farmacología , Animales , Animales Recién Nacidos , Antineoplásicos/metabolismo , Antineoplásicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Butiratos , Ácido Butírico/metabolismo , Células Cultivadas , Evaluación Preclínica de Medicamentos , Femenino , Formaldehído/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Histona Desacetilasas/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Modelos Biológicos , Miocitos Cardíacos/metabolismo , Compuestos Organofosforados , Ratas
2.
Cell Tissue Res ; 303(1): 57-67, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11236005

RESUMEN

In the ventricles of adult mammalian hearts, production of atrial natriuretic peptide (ANP) is negligible, restricted to the impulse-conducting cells, the papillary muscles, and a minority of subendocardial myocytes. ANP expression is reinduced in the ventricles of pressure-overloaded and failing hearts and is frequently used as a marker for myocyte hypertrophy. Using an immunohistochemical approach, we have characterized the size distribution of ANP-containing myocytes in the left ventricle of the spontaneously hypertensive rat (SHR) before and after chronic antihypertensive therapy and compared the results to age-matched normotensive Wistar rats (WR). Our findings show that in SHR the frequency of cells presenting ANP granularity is positively correlated with myocyte size (r=0.746, P<0.02). The highest proportion of ANP-positive myocytes (55-57%) was measured among cells of diameters 30-34 microm. In any corresponding cell size, the proportion of ANP-presenting myocytes was five- to tenfold higher in SHR than in the normotensive WR. We studied the effects of the antihypertensive drugs captopril, hydralazine, and nifedipine and found that, regardless of their effect on blood pressure or hypertrophy, all three eliminated ANP immunoproducts from the majority of the left ventricular myocytes and reduced the level of ANP mRNA, captopril being the most effective. The positive correlation between myocyte size and ANP expression was not maintained in the hearts of drug-treated SHR. Myocytes on the border of fibrotic areas or in regions of ANP presentation within the normal heart resisted the suppressive effect of the antihypertensive therapy, indicating that blood pressure or hypertrophy are not the sole correlates for ANP expression.


Asunto(s)
Antihipertensivos/farmacología , Factor Natriurético Atrial/análisis , Factor Natriurético Atrial/genética , Captopril/farmacología , Hipertensión/tratamiento farmacológico , Miocardio/química , Animales , Presión Sanguínea/fisiología , Northern Blotting , Tamaño de la Célula/efectos de los fármacos , Tamaño de la Célula/fisiología , Expresión Génica/efectos de los fármacos , Expresión Génica/fisiología , Ventrículos Cardíacos/química , Ventrículos Cardíacos/citología , Hidralazina/farmacología , Hipertensión/fisiopatología , Inmunohistoquímica , Masculino , Fibras Musculares Esqueléticas/química , Fibras Musculares Esqueléticas/citología , Miocardio/citología , Nifedipino/farmacología , Tamaño de los Órganos , ARN Mensajero/análisis , Ratas , Ratas Endogámicas SHR , Ratas Wistar , Vasodilatadores/farmacología , Función Ventricular
3.
Isr J Med Sci ; 32(12): 1212-6, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9007156

RESUMEN

The extensive use of amiodarone as an anti-arrhythmic drug is hampered by numerous side effects and by insufficient knowledge of its cellular action. The use of cell cultures for studying the mechanism of amiodarone action has been questioned, since available information has indicated that the doses employed for the experiments induce cell damage. We have defined conditions to obtain the amiodarone effect on cardiac cells in culture with no detectable damage. Amiodarone, 1 microg/ml, a concentration comparable to serum levels of the drug in acute and chronically treated humans and rats, reduces cell contractions, modifies membrane electrical properties accordingly, increases ATP content, but does not alter cell substructure or change enzyme activities. We strongly support the use of cell cultures for studying the cellular action(s) of amiodarone and offer conditions suitable for such experiments.


Asunto(s)
Amiodarona/farmacología , Antiarrítmicos/farmacología , Corazón/efectos de los fármacos , Miocardio/citología , Adenosina Trifosfato/análisis , Animales , Células Cultivadas/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Electrofisiología , Corazón/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Miocardio/química , Miocardio/enzimología , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA